Alchemab Therapeutics
Dr. Hamer is a Managing General Partner at DCVC Bio, a San Francisco venture capital fund focused on building the next generation of life science companies. He has held positions as Managing Partner and Founder of Monsanto Growth Ventures and Managing Director and Entrepreneur-in-Residence at Burrill & Co. Prior to venture capital, Dr. Hamer held senior management positions at Paradigm Genetics Inc./Icoria (NASDAQ::PDGM), including CSO, CEO and EVP for Business Development.
Dr. Hamer has a PhD in Microbiology from the University of California, Davis and was Professor of Biological Sciences at Purdue University where he was a Packard Fellow and NSF Presidential Faculty Fellow.
This person is not in the org chart
This person is not in any offices
Alchemab Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.